Evidence map›Paper›PMID 41307185›Full record

ArticleBiotechnology progress

Enhancing CHO cell recombinant protein production using a perfusion-directed host evolution approach.

Peter Amaya, Rajesh K Mistry, Susie Sou, Sonja Hess, Bijay Khanal, Zayla Schaeffer, Jie Zhu, Lina Chakrabarti

Abstract read
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peter AmayaCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Rajesh K MistryCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-9992-8735
Susie SouCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0003-4115-5159
Sonja HessDynamic Omics, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Bijay KhanalCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Zayla SchaefferBioprocess Technologies & Engineering, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Jie ZhuCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Lina ChakrabartiCell Culture & Fermentation Sciences, BioPharmaceuticals Development, R&D, AstraZeneca, Gaithersburg, Maryland, USA.ORCID 0009-0005-6376-239X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clonally derived cell lines generated from Chinese hamster ovary (CHO) cells encounter numerous stressors when cultured in high-intensity perfusion bioreactors leading to poor process performance. To circumvent this, the ability of CHO cells to adapt to different culture environments was exploited. Here host cells were selected in the presence of physical and chemical stressors associated with a perfusion environment by culturing at a high cell density in a perfusion bioreactor for 30 days. Following recovery and expansion, the performance of the resulting perfusion-evolved host was evaluated using stable transfectant pools and clones expressing biotherapeutics of different formats. Cell lines generated from the perfusion host outperformed the parental host at several fundamental stages of the clone selection process. Perfusion host-derived pools showed elevations in productivity, cell-specific productivity, end-of-run viability, and reduced lactate production in fed-batch culture. Use of the perfusion host for cell line generation resulted in an increased frequency of high-producing clones. Moreover, the perfusion host-derived clones demonstrated 30% higher productivity and improved mannose profile in the perfusion environment compared to the clones from the parental host. Furthermore, a comparative proteomic analysis between the two host types revealed unique regulatory networks that allowed us to gain insights into the underlying molecular processes influencing production performance. Taken together, the results suggest that the perfusion host may not only increase the efficiency of the cell line development process but may also serve as an efficient tool for improvement in production capability in the perfusion platform.

Indexed as

Recombinant ProteinsAnimalsBatch Cell Culture TechniquesBioreactorsCell Culture TechniquesCHO CellsCricetinaeCricetulusPerfusionRecombinant Proteinsbiomanufacturingcell line developmentCHOevolutionperfusionproductivityproteomics

Identifiers

PMID41307185
PMCPMC13055126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.